Table 1: Main clinical and laboratory data before rituximab (RTX-baseline), 2 months after rituximab cycle (BOC-baseline), and at the end of follow-up after boceprevir-based antiviral therapy (post-BOC).

RTX-baseline
(June 2011)
BOC-baseline
(September 2011)
Post-BOC
(November 2013)

GenderFemale
Age (years)63
IL28b rs12979860 T/T
Stiffness (kPa)14.51211.7
HCV titer (IU × 106/mL)0.981.39NEG
ALT (IU/L)443719
MC manifestations
Clinical
 Purpura++
 Arthralgia+++
 Weakness++
 Peripheral neuropathy
 Raynaud syndrome
 Nephritis
 Sicca syndrome++++
Laboratory
 Cryocrit (%)500
 RF (IU/mL)24<10<10
 C4 (mg/dL)91625

RTX: rituximab; BOC: boceprevir; MC: mixed cryoglobulinemia; IL28B: polymorphism of interleukin-28B; stiffness: liver stiffness as evaluated by transient elastography; kPa: kilopascal; IU: international units; ALT: alanine aminotransferase; RF: rheumatoid factor. Normal values: <40 IU/L; normal values: <10 IU/mL; normal values: from 10 to 40 mg/dL.